Kintara Therapeutics Stock Price and Value Analysis

Should you buy Kintara Therapeutics stock? (NasdaqCM:DMPI). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
  • This company has amazingly consistent growth!
  • This stock looks overpriced.
  • This company is less known than others.
  • This company is not making money.
  • This company pays no dividend.

Inside the DMPI Numbers

DMPI Price
(Kintara Therapeutics stock price per share)
$1.40
[?] PE Ratio versus Sector 100% lower than other Unknown stocks
[?] PE Ratio versus Industry 100% lower than other Unknown stocks
[?] Free Cash Flow Jitter 0%

Is Kintara Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Kintara Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy DMPI Stock?

Does Kintara Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.